Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

1.2K
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
1.2K
Renal Drug Excretion: Tubular Reabsorption01:25

Renal Drug Excretion: Tubular Reabsorption

1.2K
Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...
1.2K
Renal Drug Excretion: Overview01:15

Renal Drug Excretion: Overview

1.1K
As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules...
1.1K
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

408
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
408
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

2.2K
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
2.2K
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

362
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
362

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Implementation and outcomes of a multifaceted care model for people experiencing homelessness and people who inject drugs hospitalized with complicated infections.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2026
Same author

Utilization of Cefiderocol in a Case of Extensively Drug-Resistant <i>Klebsiella pneumoniae</i> Prostatitis and Recurrent Urinary Tract Infection.

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians·2026
Same author

Impact of incorporating electronic medical record tools on optimal antibiotic durations at discharge for uncomplicated community-acquired pneumonia: a quasi-experimental study.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2026
Same author

Implementation of an interruptive electronic health record alert improves optimal antibiotic prescribing in ambulatory patients with acute bacterial sinusitis: a quasi-experiment.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2026
Same author

A full educational resource review of grey literature resources for vancomycin dosing tutorials.

JAC-antimicrobial resistance·2026
Same author

Discharge Delays and Costs Associated With Outpatient Parenteral Antimicrobial Therapy for Multidrug-Resistant Organisms: A Retrospective Cohort Study.

Open forum infectious diseases·2026

Related Experiment Video

Updated: Apr 23, 2026

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats
06:38

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats

Published on: March 11, 2016

13.2K

Vancomycin-associated renal dysfunction: where are we now?

Joseph J Carreno1, Rachel M Kenney, Ben Lomaestro

  • 1Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, Albany, New York.

Pharmacotherapy
|September 16, 2014
PubMed
Summary
This summary is machine-generated.

Vancomycin-associated nephrotoxicity is a significant concern, linked to risk factors like high drug exposure and concurrent therapies. This toxicity can worsen patient outcomes, including longer hospital stays and increased mortality.

Keywords:
acute kidney injurynephrotoxicityvancomycin

More Related Videos

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

7.9K
Direct Drug Delivery to Kidney via the Renal Artery
11:18

Direct Drug Delivery to Kidney via the Renal Artery

Published on: April 17, 2021

8.3K

Related Experiment Videos

Last Updated: Apr 23, 2026

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats
06:38

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats

Published on: March 11, 2016

13.2K
Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

7.9K
Direct Drug Delivery to Kidney via the Renal Artery
11:18

Direct Drug Delivery to Kidney via the Renal Artery

Published on: April 17, 2021

8.3K

Area of Science:

  • Nephrology
  • Clinical Pharmacology
  • Infectious Diseases

Background:

  • Vancomycin has been used clinically for over 60 years.
  • Vancomycin-associated nephrotoxicity is a well-documented adverse effect.
  • Understanding risk factors and outcomes is crucial for patient safety.

Purpose of the Study:

  • To review current evidence on vancomycin-associated nephrotoxicity.
  • To explore risk factors and clinical outcomes associated with this toxicity.
  • To identify future research directions for improving patient safety.

Main Methods:

  • Literature review of existing evidence on vancomycin-associated nephrotoxicity.
  • Analysis of risk factors including drug exposure, host susceptibility, and concurrent therapies.
  • Examination of clinical outcomes such as prolonged hospitalization, mortality, and renal replacement therapy.

Main Results:

  • Key risk factors for vancomycin nephrotoxicity include high trough levels (≥15 mg/L), large area under the curve, and prolonged duration of therapy.
  • Host susceptibility factors include increased body weight, pre-existing renal dysfunction, and critical illness.
  • Concurrent nephrotoxic therapy significantly increases the risk of vancomycin-induced kidney damage.

Conclusions:

  • Vancomycin-associated nephrotoxicity is linked to adverse clinical outcomes, including extended hospital stays, increased mortality, and the need for renal replacement therapy.
  • The precise contribution of vancomycin-induced nephrotoxicity to these outcomes requires further investigation.
  • Future research should focus on strategies to mitigate vancomycin-related kidney injury and enhance patient safety.